This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Exclusion Criteria

• •Treatment with SGLT2 inhibitors and/or phosphodiesterase inhibitors, nitrates or riociguat, from screening (Visit 1) or within 5 half-lives before randomisation whatever is earlier.
• •Any laboratory value more than 3 times above upper limit of normal (ULN) at screening (Visit 1) or any other laboratory value outside the reference range and clinically relevant (for safe participation) in the investigator judgment
• •Confirmed non-diabetic renal disease in the opinion of investigator
• •Any other medical condition that in the investigator's opinion poses a safety risk for the patient or may interfere with the study objectives including
• •* symptomatic heart failure (NYHA III/IV),
• •* known history of tachycardia and/or atrial fibrillation
• •* clinically relevant arrhythmias
• •* coronary heart disease not compensated by medical treatment (supine pulse rate \>70 beats per minute, existing angina pectoris)
• •* \<6 months after myocardial infarction.
• •Medical history of cancer or treatment for cancer in the last two years prior to Visit 1 (except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix, and prostatic cancer of low grade \[T1 or T2\] is exempted)
• •Surgery or trauma with significant blood loss (investigator's judgement) within the last 3 months prior to informed consent or significant blood donation (investigator's judgement) within four weeks prior to first administration of study medication or planned during the trial
• •Previous randomization in this trial
• •Currently enrolled in another investigational device or drug study, i.e., less than 30 days since ending another investigational device or drug study(s), or receiving other investigational treatment(s)
• •Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes them an unreliable study subject or unlikely to complete the trial
• •Women of childbearing potential